Characterization of [3H]alprazolam binding to central benzodiazepine receptors

Polycyclic cage structures as lipophilic scaffolds for neuroactive drugs

Polycyclic cage scaffolds have been successfully used in the development of numerous lead compounds demonstrating activity in the central nervous system (CNS). Several neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, and stroke, as well as drug abuse, can be modulated with polycyclic cage derivatives. These cage moieties, including adamantane and pentacycloundecane derivatives, improve the pharmacokinetic and pharmacodynamic properties of conjugated parent drugs and serve as an important scaffold in the design of therapeutically active agents for the treatment of neurological disorders. In this Minireview, we focus on the recent developments in the field of polycyclic cage compounds, as well as the relationship between the lipophilic character of these cage-derived drugs and the ability of such compounds to target and reach the CNS and improve the pharmacodynamic properties of compounds conjugated to it.

Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam

The pharmacokinetics and pharmacodynamics of the benzodiazepine alprazolam (1 mg, administered orally) were compared between eight patients with panic disorder and eight age- and sex-matched healthy volunteers. Subjects received orally administered placebo and alprazolam in a randomized, double-blind, single-dose crossover study. The elimination half-life, time of maximum plasma concentration, maximum concentration, volume of distribution, and clearance of alprazolam were similar for both groups. For each cohort, alprazolam treatment (vs. placebo) produced significant changes in typical benzodiazepine agonist effects, such as increased sedation and impaired cognitive performance on the digit-symbol substitution test. For the panic disorder group only, there was a significant increase in the subjective rating of"contented" and a reduction in the rating of "easily irritated." For the healthy volunteer group, alprazolam produced increases in ratings of "fatigued" and "slowed thinking," but also increases in ratings of "relaxed." In each group, alprazolam significantly increased the electroencephalographic (EEG) measure of relative beta amplitude (range, 13-30 Hz) compared with placebo. Concentration-EEG response curves fit a sigmoid E(max) model, and there was greater sensitivity to EEG effects, as measured by a 28% reduction in the EC50 value, in the panic disorder group compared with healthy control subjects. After alprazolam treatment, there was increased sensitivity to EEG and mood effects and fewer aversive effects in the panic disorder group compared with healthy subjects. There were no differences in the pharmacodynamic measures of sedation and cognition or differences in pharmacokinetics between the two groups.

Acute effects of benzodiazepines on operant behavior and in vivo receptor binding in mice

Lorazepam and alprazolam produced dose-dependent decreases in the rate of fixed-ratio (FR) 20 schedules of food presentation in which either a nose-poke or a lever-press defined the operant and under a fixed-interval (FI) 2-min lever-press schedule of food presentation. In contrast, under FI 2-min and differential reinforcement of low response rate (DRL) 20-s schedules of nose-poke responding for food, intermediate doses of alprazolam produced increases in response rate. Lorazepam, however, only decreased overall response rates under the FI schedule and produced some increases in responding under the DRL schedule. Acute in vivo benzodiazepine receptor binding experiments showed that low to intermediate doses of alprazolam produced significant increases in the binding of [3H]flumazenil in all brain areas tested, while lorazepam produced increases in the brain stem only. The acute effects on binding produced by both drugs were positively and significantly correlated with their acute effects on response rate only under the FR lever-press procedure. These results indicate that the effects of benzodiazepines on in vivo binding may be related to their effects on FR lever-press responding.

Effects of alprazolam on anxiety-related behavior of rats in a modified forced-swim test employing straw suspension

The present study was undertaken to examine how the triazolobenzodiazepine derivative, alprazolam, which possesses anxiolytic activity in man and anticonflict effects in animals, could affect both the duration of immobility and the incidence of straw-climbing behavior of rats in a modified forced-swim (MFS) test. After a 5-min test of forced swimming, four straws were suspended just above the surface of the water and subsequently the straw-climbing trials were counted for 5 min as an index of escape behaviors induced by negative emotionality (anxiety and/or fear). Rats were injected IP with either alprazolam (0.1, 0.2, 1, and 2 mg/kg) or its vehicle 30 min before testing. Alprazolam prolonged the duration of immobility and inhibited the straw-climbing counts in a dose-dependent manner. This effect is in the same direction as the effect shown by an anxiolytic benzodiazepine such as diazepam. The results suggest that alprazolam may possess anxiolytic effects at lower doses, whereas at a high dose of 2 mg/kg this compound might elicit sedation, concomitantly with its anxiolytic and/or antipanic effects. In addition, it appears that alprazolam is more potent than diazepam in the MFS test following a single-injection protocol.